RAD001 (Everolimus, mTOR inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-18 — RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma: Phase I/II dose-escalation trial evaluating RAD001 (everolimus) in relapsed/refractory hematologic malignancies including agnogenic myeloid metaplasia (myelofibrosis), CLL, ALL, AML, CML blast phase, T-cell leukemia, and mantle cell lymphoma; primary endpoint is MTD and efficacy (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
18-jun-2026
novelty 3
per-area 3
introduces